Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
DTaP (also DTPa and TDaP) is a combined vaccine against diphtheria, tetanus, and pertussis, in which the pertussis component is acellular. This is in contrast to whole-cell, inactivated DTP (aka DTwP). The acellular vaccine uses selected antigens of the pertussis pathogen to induce immunity. Because it uses fewer antigens than the whole cell vaccines, it is considered safer, but it is also more expensive. Recent research suggests that the DTP vaccine is more effective than DTaP in conferring immunity; this is because DTaP's narrower antigen base is less effective against current pathogen strains.
Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Adult and Pediatric are the major drivers for the industry.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Sanofi Pasteur
GlaxoSmithKline
Protein Sciences Corporation
Novartis AG
Seqirus
Merck Sharp & Dohme Corp
Astellas Pharma US
Pfizer Inc
Johnson & Johnson
Lanzhou Institute of Biological Products Co., Ltd
AstraZeneca
Emergent BioSolutions Inc
Segment by Type
Immune DTaP Vaccine
Therapy DTaP Vaccine
Segment by Application
Adult
Pediatric
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine introduction, etc. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Table of Content
1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Overview
1.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Overview
1.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Segment by Type
1.2.1 Immune DTaP Vaccine
1.2.2 Therapy DTaP Vaccine
1.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type
1.3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Overview by Type (2018-2029)
1.3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historic Market Size Review by Type (2018-2024)
1.3.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Breakdown by Type (2018-2024)
1.4.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Breakdown by Type (2018-2024)
2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Competition by Company
2.1 Global Top Players by Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (2018-2024)
2.2 Global Top Players by Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2018-2024)
2.3 Global Top Players by Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price (2018-2024)
2.4 Global Top Manufacturers Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Base Distribution, Sales Area, Product Type
2.5 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Competitive Situation and Trends
2.5.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine as of 2022)
2.7 Date of Key Manufacturers Enter into Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market
2.8 Key Manufacturers Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Status and Outlook by Region
3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historic Market Size by Region
3.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Region (2018-2024)
3.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Region (2018-2024)
3.2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Market Size by Region
3.3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Region (2024-2029)
3.3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Region (2024-2029)
3.3.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Application
4.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Segment by Application
4.1.1 Adult
4.1.2 Pediatric
4.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application
4.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Overview by Application (2018-2029)
4.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historic Market Size Review by Application (2018-2024)
4.2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Breakdown by Application (2018-2024)
4.3.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Breakdown by Application (2018-2024)
5 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Country
5.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historic Market Size by Country
5.1.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2018-2024)
5.1.3 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Country (2018-2024)
5.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Market Size by Country
5.2.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2024-2029)
5.2.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Country (2024-2029)
6 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Country
6.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historic Market Size by Country
6.1.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2018-2024)
6.1.3 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Country (2018-2024)
6.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Market Size by Country
6.2.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2024-2029)
6.2.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Country (2024-2029)
7 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Region
7.1 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historic Market Size by Region
7.1.1 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Market Size by Region
7.2.1 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Region (2024-2029)
8 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Country
8.1 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historic Market Size by Country
8.1.1 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2018-2024)
8.1.3 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Country (2018-2024)
8.2 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Market Size by Country
8.2.1 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2024-2029)
8.2.2 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Country (2024-2029)
9 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Country
9.1 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historic Market Size by Country
9.1.1 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Market Size by Country
9.2.1 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Sanofi Pasteur
10.1.1 Sanofi Pasteur Company Information
10.1.2 Sanofi Pasteur Introduction and Business Overview
10.1.3 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
10.1.5 Sanofi Pasteur Recent Development
10.2 GlaxoSmithKline
10.2.1 GlaxoSmithKline Company Information
10.2.2 GlaxoSmithKline Introduction and Business Overview
10.2.3 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2024)
10.2.4 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
10.2.5 GlaxoSmithKline Recent Development
10.3 Protein Sciences Corporation
10.3.1 Protein Sciences Corporation Company Information
10.3.2 Protein Sciences Corporation Introduction and Business Overview
10.3.3 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
10.3.5 Protein Sciences Corporation Recent Development
10.4 Novartis AG
10.4.1 Novartis AG Company Information
10.4.2 Novartis AG Introduction and Business Overview
10.4.3 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
10.4.5 Novartis AG Recent Development
10.5 Seqirus
10.5.1 Seqirus Company Information
10.5.2 Seqirus Introduction and Business Overview
10.5.3 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
10.5.5 Seqirus Recent Development
10.6 Merck Sharp & Dohme Corp
10.6.1 Merck Sharp & Dohme Corp Company Information
10.6.2 Merck Sharp & Dohme Corp Introduction and Business Overview
10.6.3 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2024)
10.6.4 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
10.6.5 Merck Sharp & Dohme Corp Recent Development
10.7 Astellas Pharma US
10.7.1 Astellas Pharma US Company Information
10.7.2 Astellas Pharma US Introduction and Business Overview
10.7.3 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
10.7.5 Astellas Pharma US Recent Development
10.8 Pfizer Inc
10.8.1 Pfizer Inc Company Information
10.8.2 Pfizer Inc Introduction and Business Overview
10.8.3 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2024)
10.8.4 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
10.8.5 Pfizer Inc Recent Development
10.9 Johnson & Johnson
10.9.1 Johnson & Johnson Company Information
10.9.2 Johnson & Johnson Introduction and Business Overview
10.9.3 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2024)
10.9.4 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
10.9.5 Johnson & Johnson Recent Development
10.10 Lanzhou Institute of Biological Products Co., Ltd
10.10.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
10.10.2 Lanzhou Institute of Biological Products Co., Ltd Introduction and Business Overview
10.10.3 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2024)
10.10.4 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
10.10.5 Lanzhou Institute of Biological Products Co., Ltd Recent Development
10.11 AstraZeneca
10.11.1 AstraZeneca Company Information
10.11.2 AstraZeneca Introduction and Business Overview
10.11.3 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2024)
10.11.4 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
10.11.5 AstraZeneca Recent Development
10.12 Emergent BioSolutions Inc
10.12.1 Emergent BioSolutions Inc Company Information
10.12.2 Emergent BioSolutions Inc Introduction and Business Overview
10.12.3 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2024)
10.12.4 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
10.12.5 Emergent BioSolutions Inc Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industrial Chain Analysis
11.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Dynamics
11.4.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Trends
11.4.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Drivers
11.4.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Challenges
11.4.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Distributors
12.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
List of Figure
List of Tables
Table 1. Major Company of Immune DTaP Vaccine
Table 2. Major Company of Therapy DTaP Vaccine
Table 3. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type 2018 VS 2022 VS 2029 (US$ Million)
Table 4. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2018-2024) & (K Doses)
Table 5. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Type (2018-2024)
Table 6. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2018-2024) & (US& Million)
Table 7. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share in Value by Type (2018-2024)
Table 8. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2018-2024) & (USD/Dose)
Table 9. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2024-2029) & (K Doses)
Table 10. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Type (2024-2029)
Table 11. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2024-2029) & (US$ Million)
Table 12. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Type (2024-2029)
Table 13. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2024-2029) & (USD/Dose)
Table 14. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2018-2024) & (K Doses)
Table 15. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2018-2024) & (US$ Million)
Table 16. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses) by Type (2018-2024)
Table 17. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2018-2024) & (US$ Million)
Table 18. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses) by Type (2018-2024)
Table 19. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2018-2024) & (US$ Million)
Table 20. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses) by Type (2018-2024)
Table 21. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2018-2024) & (US$ Million)
Table 22. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses) by Type (2018-2024)
Table 23. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2018-2024) & (US$ Million)
Table 24. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Company (2018-2024) & (K Doses)
Table 25. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Company (2018-2024)
Table 26. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 27. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Company (2018-2024)
Table 28. Global Market Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Company (2018-2024) & (USD/Dose)
Table 29. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 30. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 31. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine as of 2022)
Table 32. Date of Key Manufacturers Enter into Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market
Table 33. Key Manufacturers Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Type
Table 34. Mergers & Acquisitions, Expansion Plans
Table 35. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2029
Table 36. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2018-2024) & (K Doses)
Table 37. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Region (2018-2024)
Table 38. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2018-2024) & (US$ Million)
Table 39. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Region (2018-2024)
Table 40. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2024)
Table 41. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2024-2029) & (K Doses)
Table 42. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Region (2024-2029)
Table 43. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2024-2029) & (US$ Million)
Table 44. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Region (2024-2029)
Table 45. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2024-2029)
Table 46. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application: 2018 VS 2022 VS 2029 (US$ Million)
Table 47. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2018-2024) & (K Doses)
Table 48. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Application (2018-2024)
Table 49. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2018-2024) & (US$ Million)
Table 50. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Application (2018-2024)
Table 51. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2018-2024) & (USD/Dose)
Table 52. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2024-2029) & (K Doses)
Table 53. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Application (2024-2029)
Table 54. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2024-2029) & (US$ Million)
Table 55. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Application (2024-2029)
Table 56. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2024-2029) & (USD/Dose)
Table 57. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2018-2024) (K Doses)
Table 58. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2018-2024) & (US$ Million)
Table 59. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2018-2024) (K Doses)
Table 60. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2018-2024) & (US$ Million)
Table 61. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2018-2024) (K Doses)
Table 62. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2018-2024) & (US$ Million)
Table 63. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2018-2024) (K Doses)
Table 64. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2018-2024) & (US$ Million)
Table 65. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2018-2024) (K Doses)
Table 66. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2018-2024) & (US$ Million)
Table 67. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2018-2024) & (K Doses)
Table 68. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Country (2018-2024)
Table 69. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2018-2024) & (US$ Million)
Table 70. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Country (2018-2024)
Table 71. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2024-2029) & (K Doses)
Table 72. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Country (2024-2029)
Table 73. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2024-2029) & (US$ Million)
Table 74. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Country (2024-2029)
Table 75. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2018-2024) & (K Doses)
Table 76. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Country (2018-2024)
Table 77. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2018-2024) & (US$ Million)
Table 78. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Country (2018-2024)
Table 79. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2024-2029) & (K Doses)
Table 80. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Country (2024-2029)
Table 81. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2024-2029) & (US$ Million)
Table 82. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Country (2024-2029)
Table 83. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2018-2024) & (K Doses)
Table 84. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Region (2018-2024)
Table 85. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2018-2024) & (US$ Million)
Table 86. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Region (2018-2024)
Table 87. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2024-2029) & (K Doses)
Table 88. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Region (2024-2029)
Table 89. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2024-2029) & (US$ Million)
Table 90. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Region (2024-2029)
Table 91. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2018-2024) & (K Doses)
Table 92. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Country (2018-2024)
Table 93. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2018-2024) & (US$ Million)
Table 94. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Country (2018-2024)
Table 95. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2024-2029) & (K Doses)
Table 96. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Country (2024-2029)
Table 97. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2024-2029) & (US$ Million)
Table 98. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Country (2024-2029)
Table 99. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2018-2024) & (K Doses)
Table 100. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Country (2018-2024)
Table 101. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2018-2024) & (US$ Million)
Table 102. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Country (2018-2024)
Table 103. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2024-2029) & (K Doses)
Table 104. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Country (2024-2029)
Table 105. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2024-2029) & (US$ Million)
Table 106. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Country (2024-2029)
Table 107. Sanofi Pasteur Company Information
Table 108. Sanofi Pasteur Introduction and Business Overview
Table 109. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2024)
Table 110. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product
Table 111. Sanofi Pasteur Recent Development
Table 112. GlaxoSmithKline Company Information
Table 113. GlaxoSmithKline Introduction and Business Overview
Table 114. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2024)
Table 115. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product
Table 116. GlaxoSmithKline Recent Development
Table 117. Protein Sciences Corporation Company Information
Table 118. Protein Sciences Corporation Introduction and Business Overview
Table 119. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2024)
Table 120. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product
Table 121. Protein Sciences Corporation Recent Development
Table 122. Novartis AG Company Information
Table 123. Novartis AG Introduction and Business Overview
Table 124. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2024)
Table 125. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product
Table 126. Novartis AG Recent Development
Table 127. Seqirus Company Information
Table 128. Seqirus Introduction and Business Overview
Table 129. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2024)
Table 130. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product
Table 131. Seqirus Recent Development
Table 132. Merck Sharp & Dohme Corp Company Information
Table 133. Merck Sharp & Dohme Corp Introduction and Business Overview
Table 134. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2024)
Table 135. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product
Table 136. Merck Sharp & Dohme Corp Recent Development
Table 137. Astellas Pharma US Company Information
Table 138. Astellas Pharma US Introduction and Business Overview
Table 139. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2024)
Table 140. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product
Table 141. Astellas Pharma US Recent Development
Table 142. Pfizer Inc Company Information
Table 143. Pfizer Inc Introduction and Business Overview
Table 144. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2024)
Table 145. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product
Table 146. Pfizer Inc Recent Development
Table 147. Johnson & Johnson Company Information
Table 148. Johnson & Johnson Introduction and Business Overview
Table 149. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2024)
Table 150. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product
Table 151. Johnson & Johnson Recent Development
Table 152. Lanzhou Institute of Biological Products Co., Ltd Company Information
Table 153. Lanzhou Institute of Biological Products Co., Ltd Introduction and Business Overview
Table 154. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2024)
Table 155. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product
Table 156. Lanzhou Institute of Biological Products Co., Ltd Recent Development
Table 157. AstraZeneca Company Information
Table 158. AstraZeneca Introduction and Business Overview
Table 159. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2024)
Table 160. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product
Table 161. AstraZeneca Recent Development
Table 162. Emergent BioSolutions Inc Company Information
Table 163. Emergent BioSolutions Inc Introduction and Business Overview
Table 164. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2018-2024)
Table 165. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product
Table 166. Emergent BioSolutions Inc Recent Development
Table 167. Key Raw Materials Lists
Table 168. Raw Materials Key Suppliers Lists
Table 169. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Trends
Table 170. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Drivers
Table 171. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Challenges
Table 172. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Restraints
Table 173. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Distributors List
Table 174. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Downstream Customers
Table 175. Research Programs/Design for This Report
Table 176. Key Data Information from Secondary Sources
Table 177. Key Data Information from Primary Sources
List of Figures
Figure 1. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Picture
Figure 2. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Status and Outlook (2018-2029) & (US$ Million)
Figure 4. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Status and Outlook (2018-2029) & (K Doses)
Figure 5. Product Picture of Immune DTaP Vaccine
Figure 6. Global Immune DTaP Vaccine Sales YoY Growth (2018-2029) & (K Doses)
Figure 7. Product Picture of Therapy DTaP Vaccine
Figure 8. Global Therapy DTaP Vaccine Sales YoY Growth (2018-2029) & (K Doses)
Figure 9. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2018-2029) & (US$ Million)
Figure 10. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Type in 2022 & 2029
Figure 11. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Type in 2022
Figure 12. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Type in 2022
Figure 13. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Type in 2022
Figure 14. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Type in 2022
Figure 15. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Type in 2022
Figure 16. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Type in 2022
Figure 17. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Type in 2022
Figure 18. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Type in 2022
Figure 19. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Type in 2022
Figure 20. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Type in 2022
Figure 21. The 5 and 10 Largest Manufacturers in the World: Market Share by Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in 2022
Figure 22. The 5 and 10 Largest Manufacturers in the World: Market Share by Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue in 2022
Figure 23. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 24. Product Picture of Adult
Figure 25. Global Adult Sales YoY Growth (2018-2029) & (K Doses)
Figure 26. Product Picture of Pediatric
Figure 27. Global Pediatric Sales YoY Growth (2018-2029) & (K Doses)
Figure 28. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2018-2029) & (US$ Million)
Figure 29. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Application in 2022 & 2029
Figure 30. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Application in 2022
Figure 31. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Application in 2022
Figure 32. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Application in 2022
Figure 33. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Application in 2022
Figure 34. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Application in 2022
Figure 35. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Application in 2022
Figure 36. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Application in 2022
Figure 37. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Application in 2022
Figure 38. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Application in 2022
Figure 39. Key Raw Materials Price
Figure 40. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Cost Structure
Figure 41. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industrial Chain Analysis
Figure 42. Channels of Distribution
Figure 43. Distributors Profiles
Figure 44. Bottom-up and Top-down Approaches for This Report
Figure 45. Data Triangulation
Figure 46. Key Executives Interviewed
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices